revolutionizing the fight against cancers & infectious diseases
Today, the potential exists to expand the benefits of immune stimulation to overcome cancers and challenging infectious diseases with unmet needs; and it is clear which specific technical advancements and medical outcomes must be achieved to fulfill this potential:
- There is a need to better define and refine immune system targets in order to induce clinically relevant immune responses.
- The generation of antibodies to prevent infection must be complemented by the ability to generate highly robust, targeted T-cell immune responses capable of treating established cancerous cells and chronic infections.
- There is a need to develop antigen-specific cancer immunotherapies that are not dependent upon being patient specific and can activate – in the body! - functional, persistent, and durable T cell immune responses to help the body overcome its tolerance of its own self-made cancerous cells.
- There is a need for new cancer treatments with more favorable safety profiles (less toxicity and side effects).
- More efficient manufacturing would be beneficial.
- We require technologies that cannot replicate and cause disease.
- The “one bug, one drug” paradigm, which relies on the selection and targeting of a single pathogen strain, inadequately addresses influenza, HIV and other rapidly evolving viruses. Universal protection against multiple existing as well as newly emerging strains of a virus is imperative.
The rapidly advancing science of genomics along with an array of technical innovations make commercializing transformational technology with the above characteristics a realistic goal. The opportunity represented by such an achievement is substantial in its medical and commercial implications.
Our DNA-based immunotherapy technology platform has the potential to fulfill all these characteristics. Using this technology, Inovio’s goal is to develop transformative immunotherapy products that address the vast unmet needs in cancers and infectious diseases. With validating clinical efficacy data from our HPV caused cervical dysplasia study and best-in-class immune responses generated from human studies in multiple disease areas, our technology is making big strides toward this important goal.
Page 'Breadcrumb' Navigation